Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Advanced/Recurrent Lung Cancer or Mesothelioma

Trial Profile

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Advanced/Recurrent Lung Cancer or Mesothelioma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BIW 8962 (Primary)
  • Indications Lung cancer; Mesothelioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin Korea
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 18 Oct 2017 Results assessing the safety and preliminary clinical efficacy of BIW-8962 administered as monotherapy in patients with previously treated lung cancer, presented at the 18th World Conference on Lung Cancer.
    • 13 Dec 2016 Status changed from active, no longer recruiting to discontinued due to lack of efficacy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top